Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
Here’s Why Paul Prescott Has (NASDAQ: AMIX) Sitting at the Top of His Watchlist This Monday, June 22, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At AMIX While It’s Still Early… June 22, 2026 Dear Reader, For the roughly 50,000 Americans diagnosed with pancreatic cancer each year, the disease is brutal — but the pain it causes can be its own separate ordeal, often outrunning even high-dose opioids and the nerve blocks meant to control it. A company based in The Woodlands, Texas, has spent the last several years developing something unusual: a catheter that travels through the body's own blood vessels to reach the precise nerves carrying that pain, treats them, and then verifies in real time that the right ones were silenced. The first human results, presented this spring across a string of major medical conferences, are worth a closer look on their own merits. Which is why Autonomix Medical, Inc. (NASDAQ: AMIX) is topping our watchlist this morning—Monday, June 22, 2026. But keep in mind, AMIX has less than 12M shares listed in its float. When companies have small floats like this the potential exists for big moves if demand begins to shift. In fact, analyst Anthony Vendetti of Maxim Group has published a $2 target on AMIX, while healthcare analyst Jeffrey S. Cohen of Ladenburg Thalmann Co. Inc. reportedly holds a $3.60 target. Those figures stand well above AMIX’s recent $0.38 range, What Autonomix Medical, Inc. (NASDAQ: AMIX) is building
Autonomix Medical is a development-stage medical device company working on the peripheral nervous system — the network of nerves outside the brain and spinal cord. Its platform is built around a principle the company sums up as "sense, treat, and verify": a catheter-based system that maps overactive nerve activity, ablates the target nerves with radiofrequency energy, then re-checks the signal to confirm the treatment worked. What makes this technically hard is sensitivity. According to the company's June 2026 corporate presentation, existing cardiac sensing technologies detect activity down to roughly 100 microvolts, while the neuronal signaling traveling through a vessel wall is typically below 5 microvolts — far fainter than current tools can resolve. Autonomix's answer is a proprietary 1-2 mm sensory microchip paired with a custom antenna array, positioned so the signal travels only millimeters before being processed, which the company says preserves signal integrity and allows high-resolution, multi-channel capture for directional targeting. The other half of the idea is verification. Today, the presentation notes, neuronal RF ablation procedures are effective but performed essentially "blind" — physicians lack a way to target, differentiate, or confirm what they treated. The "verify" step is meant to close that gap. The company describes this as a broad platform, with an extensive IP portfolio it puts at more than 120 patents issued and pending.
What the first human trial showed
Autonomix's first-in-human proof-of-concept trial ("PoC 1") enrolled 20 patients at a single clinical site, treating intractable pain associated with pancreatic cancer through transvascular nerve ablation. The presentation is specific about who responded and who didn't, which matters for reading the numbers honestly: of the 20 enrolled, three patients with brachial access showed no improvement, and one patient was enrolled but not treated because an existing celiac trunk stenosis prevented catheter placement. The efficacy results below are drawn from the 16 femoral-access responders. Among those responding patients, the reported pain reduction was substantial and durable. The company's data shows a mean VAS pain-score reduction of 53% at 7 days, 59% at 4-6 weeks, and 66% at the 3-month post-hoc mark — a drop from a mean baseline of 7.81 (severe) down to 2.67 (mild). For context, the presentation cites the clinical literature placing a 20% VAS reduction as the threshold for clinically meaningful pain relief.
The opi-oid-use figures are equally notable: 100% of responders required zero opi-oid use at the 3-month follow-up, and the company reports a 77% improvement in global quality of health among that group. On safety, Autonomix reports no device- or procedure-related serious adverse events, while being transparent that a number of patients succumbed to their underlying disease during follow-up — eight responders before the 3-month mark — which the company attributes to disease progression, not the procedure. Where the program goes next
On the strength of PoC 1, Autonomix has moved to a follow-on "PoC 2" phase, also enrolling 20 patients at a single site. According to the presentation, PoC 2 is designed to refine the procedural protocol, evaluate the company's sensing and RF ablation catheters together, and extend the approach to additional visceral cancers that signal pain through the celiac plexus — stomach, liver, and bile duct — as well as earlier-stage pancreatic cancer. The data is meant to inform the design of a future U.S. clinical trial. The company lays out a regulatory path running from the PoC studies through a U.S. IDE clinical trial to an FDA De Novo submission, targeting potential De Novo clearance in 2028 for the pancreatic cancer-related pain indication. Beyond that lead indication, Autonomix frames the platform as applicable across chronic pain, cardiovascular, and pulmonary conditions.
A spring of external validation
What caught my attention is less any single result than the cadence of independent, peer-facing recognition the data has drawn this year. Autonomix's long-term pancreatic-pain data was selected for a featured abstract and podium presentation at the Society of Interventional Radiology (SIR) 2026 meeting, accepted for presentation at the European Conference on Interventional Oncology (ECIO 2026), accepted at Digestive Disease Week 2026, and accepted for EuroPCR 2026 — one of the leading courses in interventional cardiovascular medicine.
The company was also selected for the Best Innovation competition at CRT 2026 and presented at the LSI USA '26 emerging medtech summit. And in June, the clinical significance of the SIR data was the subject of a "What This Means" segment featuring Dr. Toufic Kachaamy, Chief of Medicine at City of Hope in Phoenix, who discussed how the approach to visceral cancer pain differs from existing techniques and its potential applicability beyond pancreatic cancer.
AMIX Developments in the News
June 4, 2026 — Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine — See Full Story
May 19, 2026 — Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation — See Full Story
May 18, 2026 — Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation — See Full Story
April 29, 2026 — Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation — See Full Story
April 22, 2026 — Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026 — See Full Story
April 8, 2026 — Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026 — See Full Story
March 11, 2026 — Autonomix Medical to Present at LSI USA '26 — See Full Story
March 5, 2026 — Autonomix Medical Selected for Best Innovation Competition at CRT 2026 — See Full Story
We're Starting Monday, June 22, 2026 With AMIX at the Top of Our Radar — Here's Why in 7 Points…
1. Tight Supply: With fewer than 12M shares in its float, AMIX’s small float could have the potential to witness big moves if demand begins to shift. 2. Analyst’s Take: AMIX has published analyst targets of $2 from Maxim Group's Anthony Vendetti and $3.60 from Ladenburg Thalmann's Jeffrey S. Cohen, figures that stand above the company's recent $0.38 range. 3. Pain Relief Results: AMIX reported mean pain-score reductions of 53% at 7 days, 59% at 4–6 weeks, and 66% at the 3-month mark among responding patients in its first human study. 4. Real-Time Nerve Targeting: AMIX has developed a catheter-based "sense, treat, and verify" system designed to identify, treat, and confirm targeted nerve activity in real time. 5. Broader Indication Pursuit: AMIX has already advanced into its PoC 2 phase, which is designed to refine the procedure and evaluate additional visceral cancer pain indications. 6. Major Medical Stage: AMIX data was selected for presentations at SIR 2026, ECIO 2026, Digestive Disease Week 2026, and EuroPCR 2026, placing the program before multiple major medical audiences. 7. IP Foundation: AMIX reports an intellectual property portfolio consisting of more than 120 patents issued and pending. Take A Look At AMIX While It’s Still Early…
From the early human pain data and the proprietary "sense, treat, and verify" catheter system, to the move into PoC 2 and the more than 120 patents issued and pending, AMIX continues to generate developments that are difficult to set aside. Its clinical results have already been presented before some of the most prominent specialist audiences in the field — SIR 2026, ECIO 2026, Digestive Disease Week 2026, and EuroPCR 2026 — as the company presses forward with its program and works to sharpen its technology. Meanwhile, a float of under 12M shares and analyst targets well above the recent $0.38 range could help AMIX attract a following if there’s any shift in demand. At Street Ideas, we bring you names we believe are worth your time and we always pair that with the same reminder. Do your own homework. Read the data yourself. The facts are what matter. AMIX still has a road ahead of it, and the milestones coming down that road should tell us a great deal about where this program is ultimately going. AMIX is the name we are locked in on this morning. Take a look at AMIX while it’s still early. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter |
0 التعليقات:
إرسال تعليق